IDEXX Laboratories, Inc. vs Health Care Select Sector SPDR Fund — how do they compare? IDEXX Laboratories, Inc. trades at $553.81 (market cap $44.48B), while Health Care Select Sector SPDR Fund trades at $159.64. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | XLV | |
|---|---|---|
Market Cap | $44.48B | — |
Sector | Health | — |
52-Week High | $766.68 | $164.48 |
52-Week Low | $520.87 | $129.01 |
Enterprise Value | $45.38B | — |
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
XLV trades at $159.25, down 1.14% on the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The healthcare ETF faces mixed sentiment with recent positive sector upgrades from State Street Investment Management but concerns about sector headwinds during earnings season. Support levels cluster around $158-160, while resistance sits at $163-165.
The healthcare sector offers defensive characteristics amid market volatility, with XLV providing diversified exposure. Key risks include patent cliffs for major holdings and election-year policy uncertainty. Analyst sentiment is cautiously optimistic given the sector's stability and innovation pipeline, though relative performance versus technology remains a concern.
Trailing returns across standard periods
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →